IMMUNORARE 5 : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers-The B3 Thymomas and Thymic Carcinomas Cohort
M. Duruisseaux, Benjamin Besse, Nicolas Girard, Éric Dansin et autres
0 citations
INRIA a CCSD electronic archive server